Products

Deflux™ is used for the treatment of VUR - a malformation of the urinary bladder which affects children and can result in severe infections of the kidney and even irreversible kidney damage. Treatment with Deflux is simple to perform and has a rapid effect. The largest single market for Deflux is the USA. Around 1 percent of all children born suffer from VUR. In many cases it disappears by itself as the child gets older. This can, however, take many years and in the meantime often long-term treatment with antibiotics is carried out. In more difficult cases, when the patient doesn’t respond to antibiotic therapy, it is necessary to either treat the patient with Deflux or more invasive surgery. Deflux represents the only minimally invasive FDA approved alternative to major ureteral reimplantation surgery. Deflux is also used for other indications outside of the United States. Worldwide net sales of Deflux in 2008 were nearly $30 million US.

Solesta™ is approved for use in Europe and Canada as an injectable treatment for fecal incontinence, a condition which afflicts millions of patients. Fecal incontinence is considered a debilitating health problem that affects about  2 percent of the general population and is four times more common in women than in men. A most common cause of fecal incontinence is trauma to the pelvic and rectal structure during vaginal delivery. Studies are also ongoing in the US and a regulatory filing for marketing approval is expected within the next 12 months.

Advancing from a start-up in May 2008, Oceana Therapeutics (OT) successfully completed a Series A preferred round of financing and is now seeking to develop a strong portfolio presence in today's high-growth specialty markets. OT is currently evaluating several approved and late stage development specialty pharmaceuticals and is focusing its product search areas on (but not limited to) pediatric endocrinology, oncology, urology, gastroenterology, endocrinology, cardiology and acute care.

Please contact products@oceanathera.com if there is a drug prospect that meets our selective criteria for promotion responsive products, high ROI capability and strong growth potential:

• Products with sales potential of $25 million or more;
• Low risk/moderate-to-high return development opportunities;
• Strong intellectual property positions;
• High gross profit margins.